4.7 Article

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

期刊

CANCER DISCOVERY
卷 11, 期 8, 页码 2014-2031

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-20-0841

关键词

-

类别

资金

  1. Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Dream Team Translational Research Grant [SU2C-AACR-DT14-14]
  2. Brenden-Colson Center for Pancreatic Care at OHSU
  3. National Institutes of Health [1U01 CA224012, U2C CA233280, R01 CA223150, R01 CA226909, R21 HD099367, U01 CA210171, P50 CA127003, U54 CA209988, R01 CA196228, R01 CA186241]
  4. Knight Cancer Institute
  5. National Institutes of Health, National Cancer Institute Human Tumor Atlas Network (HTAN) Research Center [U2C CA233280]
  6. Prospect Creek Foundation
  7. Hale Family Center for Pancreatic Cancer Research
  8. Lustgarten Foundation Dedicated Laboratory program
  9. Stand Up To Cancer
  10. Pancreatic Cancer Action Network
  11. Noble Effort Fund
  12. Wexler Family Fund
  13. Promises for Purple
  14. McCarthy Strong
  15. Finnish Cultural Foundation
  16. Orion Research Foundation
  17. Apexigen
  18. Fibrogen
  19. Inovio
  20. Janssen
  21. Lilly
  22. Oregon Clinical & Translational Research Institute (OCTRI) - National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR002369]

向作者/读者索取更多资源

Researchers have established an immune atlas of PDAC through single-cell resolution profiling, identifying leukocyte features correlated with clinical outcomes, which can serve as a valuable reference for PDAC treatment. The data can aid in deeper understanding of the PDAC immune ecosystem, identifying additional therapeutic targets, and providing predictive biomarkers for therapeutic response and resistance monitoring.
Immunotherapies targeting aspects of T cell functionality are efficacious in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) remains refractory to these treatments. Deeper understanding of the PDAC immune ecosystem is needed to identify additional therapeutic targets and predictive biomarkers for therapeutic response and resistance monitoring. To address these needs, we quantitatively evaluated leukocyte contexture in 135 human PDACs at single-cell resolution by profiling density and spatial distribution of myeloid and lymphoid cells within histopathologically defined regions of surgical resections from treatment-naive and presurgically (neoadjuvant)-treated patients and biopsy specimens from metastatic PDAC. Resultant data establish an immune atlas of PDAC heterogeneity, identify leukocyte features correlating with clinical outcomes, and, through an in silico study, provide guidance for use of PDAC tissue microarrays to optimally measure intratumoral immune heterogeneity. Atlas data have direct applicability as a reference for evaluating immune responses to investigational neoadjuvant PDAC therapeutics where pretherapy baseline specimens are not available. SIGNIFICANCE: We provide a phenotypic and spatial immune atlas of human PDAC identifying leukocyte composition at steady state and following standard neoadjuvant therapies. These data have broad utility as a resource that can inform on leukocyte responses to emerging therapies where baseline tissues were not acquired.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据